May 2007
Volume 48, Issue 13
Free
ARVO Annual Meeting Abstract  |   May 2007
Intravitreal Bevacizumab for the Treatment of Chronic or Recurrent Central Serous Chorioretinopathy
Author Affiliations & Notes
  • M. E. Torres
    Retina Service, Asociación para evitar la Ceguera en México. Hospital Dr. Luis Sánchez Bulnes., México DF., Mexico
  • O. Ustáriz-Gonzáles
    Retina Service, Asociación para evitar la Ceguera en México. Hospital Dr. Luis Sánchez Bulnes., México DF., Mexico
  • V. Kon-Jara
    Retina Service, Asociación para evitar la Ceguera en México. Hospital Dr. Luis Sánchez Bulnes., México DF., Mexico
  • G. García-Aguirre
    Retina Service, Asociación para evitar la Ceguera en México. Hospital Dr. Luis Sánchez Bulnes., México DF., Mexico
  • J. L. Díaz-Rubio
    Retina Service, Asociación para evitar la Ceguera en México. Hospital Dr. Luis Sánchez Bulnes., México DF., Mexico
  • M. Gordon-Angelozzi
    Retina Service, Asociación para evitar la Ceguera en México. Hospital Dr. Luis Sánchez Bulnes., México DF., Mexico
  • A. Solis-Vivanco
    Retina Service, Asociación para evitar la Ceguera en México. Hospital Dr. Luis Sánchez Bulnes., México DF., Mexico
  • M. Ober
    Mertz Retinal Research Center., Manhattan Eye, Ear and Throat Hospital, New York, New York
  • J. L. Guerrero-Naranjo
    Retina Service, Asociación para evitar la Ceguera en México. Hospital Dr. Luis Sánchez Bulnes., México DF., Mexico
  • H. Quiroz-Mercado
    Retina Service, Asociación para evitar la Ceguera en México. Hospital Dr. Luis Sánchez Bulnes., México DF., Mexico
  • Footnotes
    Commercial Relationships M.E. Torres, None; O. Ustáriz-Gonzáles, None; V. Kon-Jara, None; G. García-Aguirre, None; J.L. Díaz-Rubio, None; M. Gordon-Angelozzi, None; A. Solis-Vivanco, None; M. Ober, None; J.L. Guerrero-Naranjo, None; H. Quiroz-Mercado, None.
  • Footnotes
    Support None.
Investigative Ophthalmology & Visual Science May 2007, Vol.48, 290. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      M. E. Torres, O. Ustáriz-Gonzáles, V. Kon-Jara, G. García-Aguirre, J. L. Díaz-Rubio, M. Gordon-Angelozzi, A. Solis-Vivanco, M. Ober, J. L. Guerrero-Naranjo, H. Quiroz-Mercado; Intravitreal Bevacizumab for the Treatment of Chronic or Recurrent Central Serous Chorioretinopathy. Invest. Ophthalmol. Vis. Sci. 2007;48(13):290.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose:: To report the safety and efficacy of intravitreal bevacizumab as a new option in the treatment of chronic or recurrent central serous chorioretinopathy (CSC).

Methods:: Prospective, non-comparative case series. Six eyes with chronic (> 6 months symptoms) or recurrent (> 1 episode) CSC were treated with intravitreal bevacizumab (2.5mg/0.1cc). ETDRS best corrected visual acuity (BCVA), fluorescein angiography (FA), indocyanine green angiography (ICG) and optical coherent tomography (OCT) were evaluated in all cases at baseline and 1, 3, and 6 months after treatment.

Results:: Visual acuity improved in all cases at one month after treatment with resolution of symptoms and decreased neurosensory retinal and RPE detachment as demonstrated by OCT, as well as fluorescein leakage and choroidal hyperpermeability. There were no adverse events.

Conclusions:: Intravitreal bevacizumab is well tolerated and resulted in a significant improvement in visual acuity, FA, ICG and OCT. Although these results are promising, definitive recommendations of treatment require further investigations.

Clinical Trial:: www.clinicaltrials.gov APEC-0016

Keywords: retina • drug toxicity/drug effects 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×